Background: Given the increasing number of medications prescribed to children, genes with potential clinical utility for drug response were included in a PGx test panel offered to newborns. Method: Desiring a non-invasive test, we evaluated multiple buccal swabs devices. The PGx Newborn Program personnel, bilingual in English and Spanish, were recruited to conduct patient education and obtain consent. Staff received training to assure their compliance with hospital policies and procedures. The personnel for the PGx program collaborated with postpartum nurses to complete the specimen collection during the short postpartum hospital stay. Parent education materials included a brochure and a video on the hospital closed circuit television system (available in Spanish and English). Test ordering and results are integrated into the Electronic Health Records and sent to the pediatrician. Results: In the pilot phase of the project, 75% of parents readily agreed to PGx testing for their children. Currently, over 200 newborns have had a PGx since the pilot began two month ago; approximately 20 % of newborns have had variants identified. We anticipate potentially testing 6000-8000 newborns this year. Conclusion: Knowledge of PGx variants from birth will guide selection of appropriate medication when required by a child. In coming years as more medications are mapped to genes and the variant responses learned, this knowledge will have even more clinical utility.